New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 7, 2013
11:33 EDTDV, ZUMZ, PHH, AUXL, PDHHigh option volume stocks: DV ZUMZ PHH AUXL PDH
News For DV;ZUMZ;PHH;AUXL;PDH From The Last 14 Days
Check below for free stories on DV;ZUMZ;PHH;AUXL;PDH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
06:41 EDTAUXLAuxilium reports XIAFLEX milestone, triggers $10M payment
Auxilium Pharmaceuticals announced that the company will receive a $10M regulatory milestone payment from its partner Asahi Kasei Pharma Corporation. The payment is due because of the successful submission of a regulatory application to the Japanese Pharmaceutical and Medical Device Agency, or PMDA, for XIAFLEX for the treatment of Dupuytren's contracture, or DC. The review by PMDA is expected to be completed by mid-2015. XIAFLEX is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord and, in the U.S. for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy.
July 18, 2014
09:35 EDTPHHPHH Corp. initiated with a Buy at Sidoti
Subscribe for More Information
08:33 EDTDVDeVry discloses receipt of letter from NY AG regarding ads, marketing
DeVry disclosed in a regulatory filing that on July 15 DeVry Group received a letter from the Office of the Attorney General of the State of New York requesting cooperation with the NYOAG’s inquiry into whether recent television advertisements and website marketing regarding DeVry University may have violated federal and state laws prohibiting false advertising and deceptive practices. The letter requests relevant information from January 1, 2011, to the present to enable NYOAG to make a determination of what action, if any, is warranted. "DeVry Group intends to provide the Office of the Attorney General with its full cooperation with a view toward demonstrating the compliant nature of its practices. The timing or outcome of this matter, or its possible impact on DeVry Group’s business, financial condition or results of operations, cannot be predicted at this time," the company stated.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use